Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bordeaux
Clinical trial register · France

Clinical Trials in Bordeaux, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Bordeaux126 AstraZeneca62 Assistance Publique - Hôpitaux de Paris44 UNICANCER40 Novartis Pharmaceuticals35 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Bordeaux

35 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Bordeaux
2026-06-12
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Bordeaux, Saint-Herblain
2026-05-19
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
650
Bordeaux, Brest, Montpellier, Paris, Pierre-Bénite, Rouen
2026-04-16
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Bordeaux, Brest, Créteil, Nice, Reims, Rouen, Toulouse
2026-03-09
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Bordeaux, Clermont-Ferrand, Nantes, Villejuif
2025-12-05
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Paris
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Bordeaux, Paris
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bordeaux, Clermont-Ferrand, Lille, Marseille, Nice, Nîmes, Paris, Poitiers
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Bordeaux, Brest, Le Kremlin-Bicêtre, Lille
2025-06-20
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Bordeaux, Brest, Lille
2025-04-22
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Bordeaux, Saint-Herblain
2025-04-03
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
2025-02-18
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Bordeaux, Nice, Paris, Strasbourg, Toulouse
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Bordeaux, Clermont-Ferrand, Marseille, Montpellier, Nantes, Paris, Strasbourg, Toulouse
2024-09-04
Active, closed
Novartis Pharmaceuticals
Observational
192
Nice, Antony, Bordeaux, Brest, Calais, Dijon, La Rochelle, Le Mans
2024-06-17
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Saint-Cloud, Bordeaux, Bron, Clermont-Ferrand, Rouen, Saint-Herblain
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Bordeaux, Paris, Rouen, Toulouse, Tours
2024-02-28
Active, closed
Novartis Pharmaceuticals
Observational
302
Angers, Paris, Agen, Altkirch, Amiens, Belfort, Bordeaux, Boulogne-sur-Mer
2023-12-21
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Angers, Bordeaux, Bron, Caen, Dijon, Lille, Marseille, Montpellier
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Saint-Cloud, Bordeaux, Saint-Herblain
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Bordeaux, Marseille, Toulouse
2023-06-27
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Avignon, Besançon, Béziers, Bobigny, Bordeaux, Caen, Compiègne, Dijon
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Angers, Antony, Bordeaux, Brest, Montpellier, Nice, Paris, Pierre-Bénite
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice
2022-11-21
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Bordeaux, Lyon, Marseille, Nantes, Paris, Vandœuvre-lès-Nancy
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Besançon, Bordeaux, Grenoble, Lyon, Marseille, Poitiers, Toulouse, Vandœuvre-lès-Nancy
2022-07-14
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Bordeaux, Lille, Paris, Poitiers
2021-12-27
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bordeaux, Lyon, Nantes, Paris
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Montpellier, Bordeaux, Clermont-Ferrand, Marseille, Vandœuvre-lès-Nancy
2021-07-30
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Angers, Bordeaux, Clermont-Ferrand, Lyon, Paris, Villejuif
2021-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy
2021-06-09
Active, closed
Novartis Pharmaceuticals
Phase 2
236
Bordeaux, Dijon, Paris, Tours
2021-04-19
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Bordeaux, Le Kremlin-Bicêtre, Marseille, Montpellier, Toulouse
2013-07-26
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/bordeaux

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Bordeaux that also match the filters currently applied.

How many clinical trials are recruiting in Bordeaux?

17 of the 35 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bordeaux), 35 studies
PhaseStudiesRecruitingShare
Phase 313437.1%
Phase 1/28622.9%
Phase 26317.1%
Phase 14211.4%
Observational205.7%
Phase 2/3112.9%
Phase 4112.9%

Most active sponsors

Lead sponsors with the most studies (Bordeaux)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3517
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.